Aripiprazole for the treatment of psychotic symptoms in patients with dementia with Lewy bodies: a case series

Yuka Sugawara Kikuchi, Tetsuo ShimizuDepartment of Neuropsychiatry, Akita University Graduate School of Medicine, Akita 010-8543, JapanPurpose: The core features of dementia with Lewy bodies (DLB) are cognitive fluctuations, visual hallucinations, and parkinsonian symptoms. Although there have been...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sugawara Kikuchi Y, Shimizu T
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	Aripiprazole Lewy bodies Dementia Psychotic symptoms Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/c2cabf478b5c4f398faeb7e7efa91910
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c2cabf478b5c4f398faeb7e7efa91910
record_format	dspace
spelling	oai:doaj.org-article:c2cabf478b5c4f398faeb7e7efa919102021-12-02T09:11:05ZAripiprazole for the treatment of psychotic symptoms in patients with dementia with Lewy bodies: a case series1178-2021https://doaj.org/article/c2cabf478b5c4f398faeb7e7efa919102019-02-01T00:00:00Zhttps://www.dovepress.com/aripiprazole-for-the-treatment-of-psychotic-symptoms-in-patients-with--peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Yuka Sugawara Kikuchi, Tetsuo ShimizuDepartment of Neuropsychiatry, Akita University Graduate School of Medicine, Akita 010-8543, JapanPurpose: The core features of dementia with Lewy bodies (DLB) are cognitive fluctuations, visual hallucinations, and parkinsonian symptoms. Although there have been several reports on the efficacy of treatments for psychotic symptoms in patients with DLB, little is known regarding the treatment effects of aripiprazole. The aim of this study was to evaluate the efficacy and safety of aripiprazole for the treatment of psychotic symptoms in patients with DLB.Patients and methods: We employed a 10-week, open-label study design with 11 patients who met the criteria for DLB. The patients had previously experienced persistent or intermittent delusions, hallucinations, or both for at least 1 month. Aripiprazole was initiated at a low dose (3 or 6 mg/day) and titrated to higher doses at 2-week intervals or more rapidly, as needed. The Neuropsychiatric Inventory (NPI), Brief Psychiatric Rating Scale (BPRS), and Clinical Global Impression-Severity (CGI-S) were administered at baseline and 1, 2, 4, 8, and 10 weeks later. The Simpson–Angus Scale (SAS), Clinical Dementia Rating (CDR), and Mini-Mental State Examination (MMSE) Scale were evaluated at baseline and at week 10. The NPI, CGI-S, and BPRS scores were compared between the baseline and each assessment point and between each assessment point and the one before assessment point. The SAS, CDR, and MMSE scores were compared between the baseline and the end point.Results: The mean NPI and BPRS scores improved until the fourth week; they significantly decreased at each assessment point compared to the previous one. Afterward, improvements slowed and continued without significant decrease. The median SAS scores significantly decreased at the end point compared to the baseline (P<0.05). The median MMSE score was higher at the end point than at the baseline (P<0.05).Conclusion: This study showed that aripiprazole may be effective and well tolerated for the treatment of psychotic symptoms in patients with DLB. Keywords: aripiprazole, Lewy bodies, dementia, psychotic symptomsSugawara Kikuchi YShimizu TDove Medical PressarticleAripiprazoleLewy bodiesDementiaPsychotic symptomsNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 15, Pp 543-547 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Aripiprazole Lewy bodies Dementia Psychotic symptoms Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Aripiprazole Lewy bodies Dementia Psychotic symptoms Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Sugawara Kikuchi Y Shimizu T Aripiprazole for the treatment of psychotic symptoms in patients with dementia with Lewy bodies: a case series
description	Yuka Sugawara Kikuchi, Tetsuo ShimizuDepartment of Neuropsychiatry, Akita University Graduate School of Medicine, Akita 010-8543, JapanPurpose: The core features of dementia with Lewy bodies (DLB) are cognitive fluctuations, visual hallucinations, and parkinsonian symptoms. Although there have been several reports on the efficacy of treatments for psychotic symptoms in patients with DLB, little is known regarding the treatment effects of aripiprazole. The aim of this study was to evaluate the efficacy and safety of aripiprazole for the treatment of psychotic symptoms in patients with DLB.Patients and methods: We employed a 10-week, open-label study design with 11 patients who met the criteria for DLB. The patients had previously experienced persistent or intermittent delusions, hallucinations, or both for at least 1 month. Aripiprazole was initiated at a low dose (3 or 6 mg/day) and titrated to higher doses at 2-week intervals or more rapidly, as needed. The Neuropsychiatric Inventory (NPI), Brief Psychiatric Rating Scale (BPRS), and Clinical Global Impression-Severity (CGI-S) were administered at baseline and 1, 2, 4, 8, and 10 weeks later. The Simpson–Angus Scale (SAS), Clinical Dementia Rating (CDR), and Mini-Mental State Examination (MMSE) Scale were evaluated at baseline and at week 10. The NPI, CGI-S, and BPRS scores were compared between the baseline and each assessment point and between each assessment point and the one before assessment point. The SAS, CDR, and MMSE scores were compared between the baseline and the end point.Results: The mean NPI and BPRS scores improved until the fourth week; they significantly decreased at each assessment point compared to the previous one. Afterward, improvements slowed and continued without significant decrease. The median SAS scores significantly decreased at the end point compared to the baseline (P<0.05). The median MMSE score was higher at the end point than at the baseline (P<0.05).Conclusion: This study showed that aripiprazole may be effective and well tolerated for the treatment of psychotic symptoms in patients with DLB. Keywords: aripiprazole, Lewy bodies, dementia, psychotic symptoms
format	article
author	Sugawara Kikuchi Y Shimizu T
author_facet	Sugawara Kikuchi Y Shimizu T
author_sort	Sugawara Kikuchi Y
title	Aripiprazole for the treatment of psychotic symptoms in patients with dementia with Lewy bodies: a case series
title_short	Aripiprazole for the treatment of psychotic symptoms in patients with dementia with Lewy bodies: a case series
title_full	Aripiprazole for the treatment of psychotic symptoms in patients with dementia with Lewy bodies: a case series
title_fullStr	Aripiprazole for the treatment of psychotic symptoms in patients with dementia with Lewy bodies: a case series
title_full_unstemmed	Aripiprazole for the treatment of psychotic symptoms in patients with dementia with Lewy bodies: a case series
title_sort	aripiprazole for the treatment of psychotic symptoms in patients with dementia with lewy bodies: a case series
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/c2cabf478b5c4f398faeb7e7efa91910
work_keys_str_mv	AT sugawarakikuchiy aripiprazoleforthetreatmentofpsychoticsymptomsinpatientswithdementiawithlewybodiesacaseseries AT shimizut aripiprazoleforthetreatmentofpsychoticsymptomsinpatientswithdementiawithlewybodiesacaseseries
_version_	1718398209376649216

Aripiprazole for the treatment of psychotic symptoms in patients with dementia with Lewy bodies: a case series

Ejemplares similares